The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The results were consistent across both the 10 mg and 40 mg treatment arms
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
Subscribe To Our Newsletter & Stay Updated
